
Ming-Wen An

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1947313/publications.pdf Version: 2024-02-01



MINC-WEN AN

#	Article	IF	CITATIONS
1	Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews, 2016, 43, 74-82.	3.4	61
2	Precision oncology: A new era of cancer clinical trials. Cancer Letters, 2017, 387, 121-126.	3.2	53
3	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. Journal of Clinical Oncology, 2014, 32, 841-850.	0.8	40
4	Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials. Clinical Cancer Research, 2011, 17, 6592-6599.	3.2	27
5	Test on existence of histology subtype-specific prognostic signatures among early stage lung adenocarcinoma and squamous cell carcinoma patients using a Cox-model based filter. Biology Direct, 2015, 10, 15.	1.9	25
6	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. Journal of the National Cancer Institute, 2015, 107, djv239.	3.0	18
7	A 2-Stage Phase II Design with Direct Assignment Option in Stage II for Initial Marker Validation. Clinical Cancer Research, 2012, 18, 4225-4233.	3.2	17
8	A Stochastic Simulator of a Blood Product Donation Environment with Demand Spikes and Supply Shocks. PLoS ONE, 2011, 6, e21752.	1.1	7
9	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. Journal of Clinical Oncology, 2015, 33, 4048-4057.	0.8	6
10	Principles of Good Clinical Trial Design. Journal of Thoracic Oncology, 2020, 15, 1277-1280.	0.5	6
11	Choosing profile doubleâ€sampling designs for survival estimation with application to President's Emergency Plan for AIDS Relief evaluation. Statistics in Medicine, 2014, 33, 2017-2029.	0.8	5
12	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemporary Clinical Trials Communications, 2020, 17, 100492.	0.5	5
13	Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. Contemporary Clinical Trials, 2014, 38, 157-162.	0.8	2
14	The Direct Assignment Option as a Modular Design Component: An Example for the Setting of Two Predefined Subgroups. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-6.	0.7	2
15	Time to progression ratio: promising new metric or just another metric?. Annals of Translational Medicine, 2016, 4, S43-S43.	0.7	1
16	Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials. Contemporary Clinical Trials Communications, 2021, 23, 100827.	0.5	0